Most Shorted Stocks
ARQT is part of our most shorted stocks screen list, indicating it has a high short interest.
ARCUTIS BIOTHERAPEUTICS INC (ARQT) Stock Price & Overview
NASDAQ:ARQT • US03969K1088
Current stock price
23.35 USD
+0.13 (+0.56%)
At close:
23.35 USD
0 (0%)
After Hours:
The current stock price of ARQT is 23.35 USD. Today ARQT is up by 0.56%. In the past month the price decreased by -1.18%. In the past year, price increased by 53.22%.
ARQT Key Statistics
52-Week Range12.42 - 31.77
Current ARQT stock price positioned within its 52-week range.
1-Month Range22.13 - 25.47
Current ARQT stock price positioned within its 1-month range.
- Market Cap
- 2.896B
- P/E
- N/A
- Fwd P/E
- 81.63
- EPS (TTM)
- -0.14
- Dividend Yield
- N/A
ARQT Stock Performance
Today
+0.56%
1 Week
+0.39%
1 Month
-1.18%
3 Months
-7.96%
Longer-term
6 Months -7.74%
1 Year +53.22%
2 Years +179.31%
3 Years +210.92%
5 Years -11.39%
10 Years N/A
ARQT Stock Chart
ARQT Stock Screens
ARQT currently appears in the following ChartMill screener lists.
ARQT Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to ARQT. When comparing the yearly performance of all stocks, ARQT is one of the better performing stocks in the market, outperforming 78.65% of all stocks.
Chartmill TA Rating
Chartmill Setup Rating
ARQT Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to ARQT. ARQT scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
ARQT Earnings
On February 25, 2026 ARQT reported an EPS of 0.13 and a revenue of 129.50M. The company beat EPS expectations (12.39% surprise) and beat revenue expectations (12.3% surprise).
Next Earnings DateMay 6, 2026
Last Earnings DateFeb 25, 2026
PeriodQ4 / 2025
EPS Reported$0.13
Revenue Reported129.503M
EPS Surprise 12.39%
Revenue Surprise 12.30%
ARQT Forecast & Estimates
14 analysts have analysed ARQT and the average price target is 35.45 USD. This implies a price increase of 51.8% is expected in the next year compared to the current price of 23.35.
For the next year, analysts expect an EPS growth of 304.31% and a revenue growth 38.1% for ARQT
Analysts
Analysts82.86
Price Target35.45 (51.82%)
EPS Next Y304.31%
Revenue Next Year38.1%
ARQT Index Membership
ARQT is currently included in the following stock indexes tracked on ChartMill.
ARQT Financial Highlights
Over the last trailing twelve months ARQT reported a non-GAAP Earnings per Share(EPS) of -0.14. The EPS increased by 87.93% compared to the year before.
Income Statements
Revenue(TTM)376.07M
Net Income(TTM)-16.14M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -3.73% | ||
| ROE | -8.52% | ||
| Debt/Equity | 0.57 |
Chartmill High Growth Momentum
EPS Q2Q%244.44%
Sales Q2Q%81.48%
EPS 1Y (TTM)87.93%
Revenue 1Y (TTM)91.34%
ARQT Ownership
Ownership
Inst Owners100.52%
Shares124.03M
Float111.87M
Ins Owners0.79%
Short Float %14.82%
Short Ratio12.7
ARQT Industry Overview
ARQT operates in the Biotechnology sub-industry within the Health Care sector. This group contains 416 stocks and is scored by ChartMill on both price strength and growth momentum.
Industry Strength Score
56/100
Composite price performance score based on 3, 6, and 12-month returns, with more weight on recent trends.
Industry Growth Score
13/100
Composite growth score based on earnings growth, revenue growth, and profitability across the sub-industry.
Relative Performance
Each rank shows how many other sub-industries were outperformed over that timeframe.
1 Month Rank
26%
Outperformed 26% of sub-industries
3 Month Rank
50%
Outperformed 50% of sub-industries
6 Month Rank
32%
Outperformed 32% of sub-industries
Industry Fundamentals & Breadth
- Members
- 416
- New Highs
- 5.1%
- New Lows
- 4.6%
- Average ROE
- 48.5%
- Average Profit Margin
- 20.5%
- Average Operating Margin
- 33.6%
- Average P/E
- 22.9
- Average Fwd P/E
- 18.2
- Average Debt/Equity
- 2.2
ARQT Latest News, Press Relases and Analysis
19 days ago - By: Chartmill
ARQT Competitors/Peers
The largest stocks on the US markets in the "Biotechnology" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 12.59 | 373.774B | ||
| AMGN | AMGEN INC | 13.88 | 186.868B | ||
| GILD | GILEAD SCIENCES INC | 14.89 | 162.401B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 21.77 | 108.708B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.72 | 74.75B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 27.54 | 41.295B | ||
| INSM | INSMED INC | N/A | 29.427B | ||
| NTRA | NATERA INC | N/A | 29.219B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 28.56B | ||
| BIIB | BIOGEN INC | 11.44 | 27.779B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.52 | 25.042B | ||
| INCY | INCYTE CORP | 10.61 | 18.96B | ||
| MRNA | MODERNA INC | N/A | 18.219B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find more growth stocks the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About ARQT
Company Profile
Arcutis Biotherapeutics, Inc. engages in the development and commercialization of treatments for dermatological diseases. The company is headquartered in Westlake Village, California and currently employs 354 full-time employees. The company went IPO on 2020-01-31. The firm is focused on developing and commercializing treatments for dermatological diseases with high-unmet medical needs. Its portfolio is comprised of topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. Its lead product, ZORYVE, is for the treatment of plaque psoriasis, including psoriasis in the intertriginous areas, in individuals 12 years of age or older. The ZORYVE is also indicated for topical treatment of mild to moderate atopic dermatitis. ZORYVE cream is a once-daily topical formulation of roflumilast, a potent and selective phosphodiesterase-4 (PDE4) inhibitor. The Company’s pipeline includes ARQ-255, ARQ-252, and ARQ-234. Its ARQ-255 is being developed for the treatment of alopecia areata. ARQ-252 is an alternative topical cream formulation of ivarmacitinib that the Company is developing for chronic hand eczema and vitiligo.
Company Info
IPO: 2020-01-31
ARCUTIS BIOTHERAPEUTICS INC
3027 Townsgate Road, Suite 300
Westlake Village CALIFORNIA 91361 US
CEO: Todd Franklin Watanabe
Employees: 354
Phone: 18054185006
ARCUTIS BIOTHERAPEUTICS INC / ARQT FAQ
What does ARCUTIS BIOTHERAPEUTICS INC do?
Arcutis Biotherapeutics, Inc. engages in the development and commercialization of treatments for dermatological diseases. The company is headquartered in Westlake Village, California and currently employs 354 full-time employees. The company went IPO on 2020-01-31. The firm is focused on developing and commercializing treatments for dermatological diseases with high-unmet medical needs. Its portfolio is comprised of topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. Its lead product, ZORYVE, is for the treatment of plaque psoriasis, including psoriasis in the intertriginous areas, in individuals 12 years of age or older. The ZORYVE is also indicated for topical treatment of mild to moderate atopic dermatitis. ZORYVE cream is a once-daily topical formulation of roflumilast, a potent and selective phosphodiesterase-4 (PDE4) inhibitor. The Company’s pipeline includes ARQ-255, ARQ-252, and ARQ-234. Its ARQ-255 is being developed for the treatment of alopecia areata. ARQ-252 is an alternative topical cream formulation of ivarmacitinib that the Company is developing for chronic hand eczema and vitiligo.
What is the current price of ARQT stock?
The current stock price of ARQT is 23.35 USD. The price increased by 0.56% in the last trading session.
Does ARCUTIS BIOTHERAPEUTICS INC pay dividends?
ARQT does not pay a dividend.
What is the ChartMill rating of ARCUTIS BIOTHERAPEUTICS INC stock?
ARQT has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
Can you provide the growth outlook for ARCUTIS BIOTHERAPEUTICS INC?
The Revenue of ARCUTIS BIOTHERAPEUTICS INC (ARQT) is expected to grow by 38.1% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
Can you provide the short interest for ARQT stock?
The outstanding short interest for ARCUTIS BIOTHERAPEUTICS INC (ARQT) is 14.82% of its float.